MGMT and malignant colon neoplasm: The combination of low tumor MGMT expression and nuclear DDR biomarker induction did not correlate with clinical response in this small test group—2 of 3 MGMTlow/DDR+ patients progressed within the first 2 cycles of treatment (patients 50 and 51, both patients with colon cancer).